Article Information
History
- March 8, 2022.
Article Versions
- Version 1 (February 26, 2022 - 00:30).
- Version 2 (March 2, 2022 - 08:54).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Paula Restrepo1,2,
- Sherry Bhalla1,2,
- Adolfo Aleman1,5,
- Violetta Leshchenko1,3,
- David T Melnekoff1,4,5,
- Sarita Agte1,
- Joy Jiang5,
- Deepu Madduri1,6,
- Joshua Richter1,
- Shambavi Richard1,
- Ajai Chari1,
- Hearn Jay Cho1,7,
- Sundar Jagannath1,
- Christopher J Walker8,
- Yosef Landesman8,
- Alessandro Laganà1,2,4,* and
- Samir Parekh1,*
- 1Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- 2Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- 3Department of Hematology & Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- 4Department of Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- 5Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- 6Janssen Pharmaceutical Research & Development, Raritan, NJ, United States
- 7Multiple Myeloma Research Foundation, Norwalk, CT, United States
- 8Karyopharm Therapeutics, Newton, MA, United States
- ↵*Address for Correspondence:
Dr. Alessandro Laganà, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA, alessandro.lagana{at}mssm.edu, Dr. Samir Parekh, Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA, samir.parekh{at}mssm.edu
Posted March 08, 2022.
